Nitrofurantoin Capsules USP (Monohydrate/Macrocrystals), 100 mg, 100-count Unit Dose Blisters, Rx...
FDA Drug Recall #D-0273-2019 — Class III — November 9, 2018
Recall Summary
| Recall Number | D-0273-2019 |
| Classification | Class III — Low risk |
| Date Initiated | November 9, 2018 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | AMERICAN HEALTH PACKAGING |
| Location | Columbus, OH |
| Product Type | Drugs |
| Quantity | 4508 blister packs |
Product Description
Nitrofurantoin Capsules USP (Monohydrate/Macrocrystals), 100 mg, 100-count Unit Dose Blisters, Rx only, Amerisource Health Services DBA American Health Packaging, 2550-A John Glenn Avenue Columbus, OH 43217, NDC 68084-446-01 (Individual Dose NDC: 68064-446-11)
Reason for Recall
Cross contamination with other products: This sub-recall is being initiated in support of the recall by the manufacturer (Sandoz) dated 11/1/18, which included lots that were repackaged by American Health Packaging. Sandoz stated that "These lots are being recalled due to the potential presence of unrelated ingredients (i.e. traces of active ingredients of Benazepril, Haloperidol and Perphenazine), which were identified through a manufacturing investigation."
Distribution Pattern
U.S.A. Nationwide
Lot / Code Information
Lot#: 180310, 180612, Exp 03/31/20
Other Recalls from AMERICAN HEALTH PACKAGING
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0880-2022 | Class III | Nitrofurantoin Capsules, USP (Monohydrate/Macro... | May 3, 2022 |
| D-0790-2022 | Class III | Cyanocobalamin Injection, USP, 1000 mcg per mL,... | Apr 12, 2022 |
| D-0652-2022 | Class II | Oxycodone Hydrochloride Oral Solution, USP (C-I... | Feb 22, 2022 |
| D-0451-2022 | Class II | Metoprolol Succinate Extended-Release Tablets, ... | Dec 20, 2021 |
| D-0020-2022 | Class II | GlipiZIDE Extended-Release Tablets, 2.5 mg, 30 ... | Sep 17, 2021 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.